A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II

A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II–III NSCLC

Published:2018-05 Issue:2 Volume:127 Page:259-266
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

La Fontaine Matthew,Vogel Wouter,van Diessen Judi,van Elmpt Wouter,Reymen Bart,Persson Gitte,Westman Gunnar,De Ruysscher Dirk,Belderbos José,Sonke Jan-Jakob

Funder

European Commission

Dutch Cancer Society

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference37 articles.

1. N auperin concurrent meta: meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer;Aupérin;JCO,2010

2. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy;van Diessen;Radiotherapy and Oncology,2016

3. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study;Kong;International Journal of Radiation Oncology Biology Physics,2005

4. Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer;Schytte;Acta Oncol (Madr),2014

5. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy;Belderbos;International Journal of Radiation Oncology Biology Physics,2006

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial;The Lancet Oncology;2024-09

2. Clinical use of positron emission tomography for radiotherapy planning – Medical physics considerations;Zeitschrift für Medizinische Physik;2023-02

3. Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy;Frontiers in Oncology;2022-01-07

4. « Définition des volumes cibles : quand et comment l’oncologue radiothérapeute peut-il utiliser la TEP ? »;Cancer/Radiothérapie;2019-10

5. Task Group 174 Report: Utilization of [ 18 F]Fluorodeoxyglucose Positron Emission Tomography ([ 18 F]FDG‐PET) in Radiation Therapy;Medical Physics;2019-09-06